Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

References

• Armitage J O, Carbone P P, Connors J M, Levine A, Bennett J, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906
   PubMed Web of Science ®Google Scholar
• Milligan D W, Ruiz De Elvira M C, Kolb H J, Goldstone A H, Meloni G, Rohatiner A Z, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–1026
   PubMed Web of Science ®Google Scholar
• Stone R M, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S N, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450–459
   PubMed Web of Science ®Google Scholar
• Milligan D W, Ruiz de Elvira M C, Kolb H-J, Goldstone A H, Meloni G, Rohatiner A Z, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 2001; 106: 1020–1026
   Web of Science ®Google Scholar
• Metayer C, Curtis R E, Vose J, Sobocinski K A, Horowitz M M, Bhatia S, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015–2023
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R, Bierman P J, Bishop M R, Chan W C, et al. Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison L L, Francisco L, Carter A, Liu Y, Grant M, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood 2005; 105: 4215–4222
   PubMed Web of Science ®Google Scholar
• Sobecks R M, Le Beau M M, Anastasi J, Williams S F. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1161–1165
   PubMed Web of Science ®Google Scholar
• Bhatia S, Louie A D, Bhatia R, O'Donnell M, Fung H, Kashyap A, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471
   PubMed Web of Science ®Google Scholar
• Baker K S, DeFor T E, Burns L J, Ramsay N, Neglia J, Robison L. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358
   PubMed Web of Science ®Google Scholar
• Prentice R L, Kalbfleisch J D, Peterson A V, Jr, Flournoy N, Farewell V T, Breslow N E. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554
   PubMed Web of Science ®Google Scholar
• Fine J P, Gray R J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509
   Web of Science ®Google Scholar
• Program. SSR. National Cancer Institute SEER*Stat software, Available at: www.seer.cancer.gov/seerstat version 6.1.4
   Google Scholar
• Jantunen E, Itala M, Siitonen T, Koivunen E, Leppa S, Juvonen E, et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990–2003. Eur J Haematol 2006; 77: 114–119
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11: 1654–1660
   PubMed Web of Science ®Google Scholar
• Brown J R, Yeckes H, Friedberg J W, Neuberg D, Lim H, Nadler L M, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2003; 23: 2208–2214
   Web of Science ®Google Scholar
• Laudi N, Arora M, Burns L J, Miller J, McGlave P B, Barker J N, et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 129–135
   PubMed Web of Science ®Google Scholar
• Majhail N S, Ness K K, Burns L J, Sun C L, Carter A, Francisco L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13: 1153–1159
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H E, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Glimelius B, Holowaty E, Leeuwen F, Lynch C, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932–1937
   PubMed Web of Science ®Google Scholar
• Travis L B, Gospodarowicz M, Curtis R E, Clarke A, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182–192
   PubMed Web of Science ®Google Scholar
• Travis L B, Weeks J, Curtis R E, Chaffey J T, Stovall M, Banks P M, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 565–571
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi P G, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008; 93: 1335–1342
   PubMed Web of Science ®Google Scholar
• Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004; 103: 1222–1228
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Stovall M, Holowaty E J, van Leeuwen F E, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994; 86: 1450–1457
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak M L, Arber D, Niland J, Nademanee A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593
   PubMed Web of Science ®Google Scholar
• Micallef I N, Lillington D M, Apostolidis J, Amess J, Neat M, Matthews J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955
   PubMed Web of Science ®Google Scholar
• Bhatia S, Ramsay N K, Steinbuch M, Dusenbery K, Shapiro R, Weisdorf D, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639
   PubMed Web of Science ®Google Scholar
• Curtis R E, Rowlings P A, Deeg H J, Shriner D, Socie G, Travis L, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904
   PubMed Web of Science ®Google Scholar
• Crump M, Shepherd L, Lin B. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by post-transplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma. Clin Lymph 2005; 6: 56–60
   PubMedGoogle Scholar